Stanford Medicine researchers have created a breakthrough nasal spray vaccine that protects against a wide range of respiratory viruses, bacteria, and allergens in mice, potentially replacing multiple annual shots with a single dose. The vaccine works by mimicking immune cell signals rather than targeting specific pathogens, a fundamentally different approach from all vaccines developed over the past 230 years. What Makes This Vaccine Different From Every Other Vaccine? Since Edward Jenner invented vaccination in the 1790s using cowpox to protect against smallpox, every vaccine has relied on the same core principle: antigen specificity. This means vaccines are designed to mimic a distinctive component of a specific pathogen, like the spike proteins on coronavirus surfaces, so your immune system learns to recognize and fight that exact threat. The problem is that viruses constantly mutate, which is why you need a new COVID-19 booster and flu shot every year. The Stanford team, led by Bali Pulendran, PhD, the Violetta L. Horton Professor II and a professor of microbiology and immunology, took a radically different approach. "We were interested in this idea because it sounded a bit outrageous," Pulendran said. "I think nobody was seriously entertaining that something like this could ever be possible." Instead of mimicking pathogen components, the new vaccine mimics the signals that immune cells use to communicate with each other during an infection. How Does This "Universal" Vaccine Actually Work in Your Body? The vaccine, currently known as GLA-3M-052-LS+OVA, creates what researchers call a "double whammy" defense system. It works by integrating two branches of immunity that normally work separately: the innate immune system (your body's rapid-response generalists that destroy anything deemed a threat) and the adaptive immune system (the specialized antibodies and T cells that remember specific pathogens for years). The vaccine contains two key components. First, it includes substances that directly stimulate innate immune cells in your lungs. Second, it contains a harmless antigen (an egg protein called ovalbumin) that recruits T cells into the lungs to keep the innate response active for weeks to months. This is crucial because innate immunity typically only lasts a few days, but the vaccine extends it dramatically. In the study published in Science, researchers gave mice a nasal drop of the vaccine. With three doses given a week apart, vaccinated mice were protected against SARS-CoV-2 and other coronaviruses for at least three months. The results were striking: the prolonged innate response reduced the amount of virus in the lungs by 700-fold. When viruses did slip through this initial defense, the adaptive immune response in the lungs launched in as little as three days, compared to two weeks in unvaccinated mice. What Respiratory Threats Did the Vaccine Protect Against in Testing? In the mouse study, the vaccine demonstrated protection against a remarkably broad spectrum of respiratory threats. Researchers tested the vaccine against multiple categories of pathogens and allergens: - Viral Threats: SARS-CoV-2 and other coronaviruses, demonstrating protection against multiple strains of the same virus family - Bacterial Infections: Staphylococcus aureus and Acinetobacter baumannii, both common hospital-acquired infections that pose serious health risks - Allergens: House dust mites, a common allergen that triggers respiratory symptoms in millions of people The breadth of protection was so unexpected that it surprised even the researchers. "The vaccine is a 'double whammy' against viral infection," Pulendran explained. "The prolonged innate response lowers the amount of virus in the lungs by 700-fold. And viruses that slip through this initial defense are met with a swift adaptive response in the lungs". How Did Scientists Discover This Was Even Possible? The breakthrough didn't emerge from nowhere. In 2023, Pulendran's team published research on the Bacillus Calmette-Guerin (BCG) tuberculosis vaccine, which is given to approximately 100 million newborns every year. They discovered something unusual: while the BCG vaccine induced both innate and adaptive immune responses, the innate response was sustained for several months, not just days. The researchers found that T cells recruited to the lungs as part of the adaptive response were sending signals to innate immune cells to keep them active. This discovery was the key insight. The team identified that T cells were sending cytokines, which are signaling molecules that activate pathogen-sensing receptors called toll-like receptors on innate immune cells. "In that paper, we speculated that since we now know how the tuberculosis vaccine is mediating its cross-protective effects, it would be possible to make a synthetic vaccine, perhaps a nasal spray, that has the right combination of toll-like receptor stimuli and some antigen to get the T cells into the lungs," Pulendran said. "Fast forward two and a half years and we've shown that exactly what we had speculated is feasible in mice". Steps to Understanding How This Could Change Preventive Care - Current Vaccine Limitations: Today's vaccines require annual updates because pathogens mutate. A universal vaccine could eliminate the need for yearly flu shots and COVID-19 boosters, reducing the burden on healthcare systems and improving vaccination rates - Nasal Delivery Advantage: The intranasal delivery method (a nasal spray) is more convenient than injections and may trigger stronger immune responses in the respiratory tract, where many infections begin - Pandemic Preparedness: If translated to humans, such a vaccine could provide rapid protection against emerging respiratory pathogens, potentially preventing future pandemics by providing broad protection before a new virus is fully characterized - Allergen Protection: The vaccine's ability to protect against allergens like house dust mites opens possibilities for treating allergic respiratory conditions, not just infectious diseases When Could This Vaccine Be Available to People? The research is still in early stages. The study was conducted in mice, and significant work remains before human trials can begin. Researchers must confirm that the vaccine is safe and effective in humans, determine the optimal dosing schedule, and establish how long protection lasts in people. However, the fundamental principle has been proven: a single vaccine can protect against multiple unrelated respiratory threats by harnessing the body's innate immune system in a sustained way. If successfully translated to humans, such a vaccine could fundamentally change how we approach respiratory disease prevention. Rather than getting multiple shots each year for seasonal flu, COVID-19, and other respiratory infections, people might receive a single nasal spray vaccine that provides broad protection for months. This represents a paradigm shift in vaccinology after more than two centuries of relying on antigen-specific approaches.
